Revolution Medicines Inc. Common Stock vs Seagate Technology Holdings PLC — how do they compare? Revolution Medicines Inc. Common Stock trades at $186.59 (market cap $40.32B), while Seagate Technology Holdings PLC trades at $774.65 (market cap $176.19B). The key difference: Seagate Technology Holdings PLC is far larger — about 4.4× Revolution Medicines Inc. Common Stock's market cap, and Seagate Technology Holdings PLC pays a 0.38% dividend while Revolution Medicines Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revolution Medicines Inc. Common Stock for 0 Days and Seagate Technology Holdings PLC for 41 Days on average.
| RVMD | STX | |
|---|---|---|
Market Cap | $40.32B | $176.19B |
Volume | 4,855,734 | 5,061,875 |
Sector | Health | Technology |
52-Week High | $221.15 | $1.09K |
52-Week Low | $47.50 | $211.63 |
Typical Hold Time | 0 Days | 41 Days |
Enterprise Value | $37.02B | $178.34B |
Dividend Yield | — | 0.38% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Seagate Technology (STX) trades at $807.34, up 0.21% with recent volatility driven by AI storage competition concerns. The stock shows strong profitability with 26.11% net margin and 371.53% ROE, though valuation ratios appear elevated (P/E 55.74, P/B 81.31). Recent earnings consistently beat expectations, with Q2 2026 EPS of $5.71 surpassing the $5.10 estimate. Technical indicators show bearish momentum with support at $794 and resistance at $816.
Outlook remains cautiously optimistic given strong AI-driven storage demand and analyst consensus price target of $1,130. Key risks include increased competition from Toshiba's planned production expansion and potential margin compression. The company's negative shareholder equity and high debt levels warrant monitoring, though projected 2026 revenue growth to $12.2B with $3.2B net income suggests continued operational strength.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →